490 related articles for article (PubMed ID: 18294387)
21. Blockade of B7-H1 or B7-DC induces an anti-tumor effect in a mouse pancreatic cancer model.
Okudaira K; Hokari R; Tsuzuki Y; Okada Y; Komoto S; Watanabe C; Kurihara C; Kawaguchi A; Nagao S; Azuma M; Yagita H; Miura S
Int J Oncol; 2009 Oct; 35(4):741-9. PubMed ID: 19724910
[TBL] [Abstract][Full Text] [Related]
22. Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: Analysis of 244 stage I-III patients treated with standard therapy.
Dieci MV; Tsvetkova V; Griguolo G; Miglietta F; Tasca G; Giorgi CA; Cumerlato E; Massa D; Lo Mele M; Orvieto E; Guarneri V; Conte P
Eur J Cancer; 2020 Sep; 136():7-15. PubMed ID: 32622323
[TBL] [Abstract][Full Text] [Related]
23. [Expression and significance of B7-H1 and its receptor PD-1 in human gastric carcinoma].
Liu SM; Meng Q; Zhang QX; Wang SD; Liu ZJ; Zhang XF
Zhonghua Zhong Liu Za Zhi; 2008 Mar; 30(3):192-5. PubMed ID: 18756934
[TBL] [Abstract][Full Text] [Related]
24. Expression of B7-H1 in breast cancer patients is strongly associated with high proliferative Ki-67-expressing tumor cells.
Ghebeh H; Tulbah A; Mohammed S; Elkum N; Bin Amer SM; Al-Tweigeri T; Dermime S
Int J Cancer; 2007 Aug; 121(4):751-8. PubMed ID: 17415709
[TBL] [Abstract][Full Text] [Related]
25. Tumor-infiltrating programmed death receptor-1+ dendritic cells mediate immune suppression in ovarian cancer.
Krempski J; Karyampudi L; Behrens MD; Erskine CL; Hartmann L; Dong H; Goode EL; Kalli KR; Knutson KL
J Immunol; 2011 Jun; 186(12):6905-13. PubMed ID: 21551365
[TBL] [Abstract][Full Text] [Related]
26. B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression.
Konishi J; Yamazaki K; Azuma M; Kinoshita I; Dosaka-Akita H; Nishimura M
Clin Cancer Res; 2004 Aug; 10(15):5094-100. PubMed ID: 15297412
[TBL] [Abstract][Full Text] [Related]
27. Low expressions of PD-L1 and CTLA-4 by induced CD4
Zhao L; Zhou X; Zhou X; Wang H; Gu L; Ke Y; Zhang M; Ji X; Yang X
Cytokine; 2020 Sep; 133():155119. PubMed ID: 32535334
[TBL] [Abstract][Full Text] [Related]
28. Expression of B7-H1 in inflammatory renal tubular epithelial cells.
Chen Y; Zhang J; Li J; Zou L; Zhao T; Tang Y; Wu Y
Nephron Exp Nephrol; 2006; 102(3-4):e81-92. PubMed ID: 16282703
[TBL] [Abstract][Full Text] [Related]
29. FOXP3-positive regulatory T lymphocytes and epithelial FOXP3 expression in synchronous normal, ductal carcinoma in situ, and invasive cancer of the breast.
Lal A; Chan L; Devries S; Chin K; Scott GK; Benz CC; Chen YY; Waldman FM; Hwang ES
Breast Cancer Res Treat; 2013 Jun; 139(2):381-90. PubMed ID: 23712790
[TBL] [Abstract][Full Text] [Related]
30. Foxp3 expression in melanoma cells as a possible mechanism of resistance to immune destruction.
Niu J; Jiang C; Li C; Liu L; Li K; Jian Z; Gao T
Cancer Immunol Immunother; 2011 Aug; 60(8):1109-18. PubMed ID: 21547596
[TBL] [Abstract][Full Text] [Related]
31. Association of Notch pathway down-regulation with Triple Negative/Basal-like breast carcinomas and high tumor-infiltrating FOXP3+ Tregs.
Ortiz-Martínez F; Gutiérrez-Aviñó FJ; Sanmartín E; Pomares-Navarro E; Villalba-Riquelme C; García-Martínez A; Lerma E; Peiró G
Exp Mol Pathol; 2016 Jun; 100(3):460-8. PubMed ID: 27118257
[TBL] [Abstract][Full Text] [Related]
32. B7-H3 in combination with regulatory T cell is associated with tumor progression in primary human non-small cell lung cancer.
Jin Y; Zhang P; Li J; Zhao J; Liu C; Yang F; Yang D; Gao A; Lin W; Ma X; Sun Y
Int J Clin Exp Pathol; 2015; 8(11):13987-95. PubMed ID: 26823710
[TBL] [Abstract][Full Text] [Related]
33. PTEN-deficient prostate cancer is associated with an immunosuppressive tumor microenvironment mediated by increased expression of IDO1 and infiltrating FoxP3+ T regulatory cells.
Vidotto T; Saggioro FP; Jamaspishvili T; Chesca DL; Picanço de Albuquerque CG; Reis RB; Graham CH; Berman DM; Siemens DR; Squire JA; Koti M
Prostate; 2019 Jun; 79(9):969-979. PubMed ID: 30999388
[TBL] [Abstract][Full Text] [Related]
34. Tumor-induced immune suppression of in vivo effector T-cell priming is mediated by the B7-H1/PD-1 axis and transforming growth factor beta.
Wei S; Shreiner AB; Takeshita N; Chen L; Zou W; Chang AE
Cancer Res; 2008 Jul; 68(13):5432-8. PubMed ID: 18593946
[TBL] [Abstract][Full Text] [Related]
35. B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disorders.
Wilcox RA; Feldman AL; Wada DA; Yang ZZ; Comfere NI; Dong H; Kwon ED; Novak AJ; Markovic SN; Pittelkow MR; Witzig TE; Ansell SM
Blood; 2009 Sep; 114(10):2149-58. PubMed ID: 19597183
[TBL] [Abstract][Full Text] [Related]
36. Regulatory T lymphocyte infiltration in metastatic breast cancer-an independent prognostic factor that changes with tumor progression.
Stenström J; Hedenfalk I; Hagerling C
Breast Cancer Res; 2021 Feb; 23(1):27. PubMed ID: 33602289
[TBL] [Abstract][Full Text] [Related]
37. Exploring the role CD163-labeled TAMs and FOXP3-labeled Tregs in different types of breast cancer: Reflections and putative benefits.
Shash LS; M Kamal KA; Abd Raboh NM
Indian J Pathol Microbiol; 2021; 64(1):28-37. PubMed ID: 33433406
[TBL] [Abstract][Full Text] [Related]
38. Immune phenotype of patients with stage IV metastatic inflammatory breast cancer.
Fernandez SV; MacFarlane AW; Jillab M; Arisi MF; Yearley J; Annamalai L; Gong Y; Cai KQ; Alpaugh RK; Cristofanilli M; Campbell KS
Breast Cancer Res; 2020 Dec; 22(1):134. PubMed ID: 33267869
[TBL] [Abstract][Full Text] [Related]
39. The possible regulatory effect of the PD-1/PD-L1 signaling pathway on Tregs in ovarian cancer.
Chen JX; Yi XJ; Gao SX; Sun JX
Gen Physiol Biophys; 2020 Jul; 39(4):319-330. PubMed ID: 32902402
[TBL] [Abstract][Full Text] [Related]
40. Tumor infiltrating T lymphocytes expressing FoxP3, CCR7 or PD-1 predict the outcome of prostate cancer patients subjected to salvage radiotherapy after biochemical relapse.
Nardone V; Botta C; Caraglia M; Martino EC; Ambrosio MR; Carfagno T; Tini P; Semeraro L; Misso G; Grimaldi A; Boccellino M; Facchini G; Berretta M; Vischi G; Rocca BJ; Barone A; Tassone P; Tagliaferri P; Del Vecchio MT; Pirtoli L; Correale P
Cancer Biol Ther; 2016 Nov; 17(11):1213-1220. PubMed ID: 27791459
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
